What did @dr.amybkillen actually say?
The core claim here is straightforward: oral estradiol at 1 mg/day produces a serum estradiol level of roughly 65 pg/mL, and that level is cardioprotective based on the ELITE, EPAT, and DOPS trials. She also warns against assuming transdermal estradiol offers the same benefit, saying explicitly, "I would advise caution in extrapolating these results to transdermal estradiol." Her target range for women on HRT is 65 to 125 pg/mL.
She's not citing fringe sources or selling a product here. She names three specific RCTs, points to a 2021 paper for the pharmacokinetic data, and distinguishes between what the studies showed and what can reasonably be inferred. That's a more careful presentation than most TikTok hormone content.
Does the science back this up?
Mostly, yes, with some important caveats. The ELITE trial (Hodis et al., 2016, New England Journal of Medicine) showed that oral estradiol reduced subclinical atherosclerosis progression in recently menopausal women. EPAT (Hodis et al., 2001, Annals of Internal Medicine) showed reduced carotid intima-media thickness. DOPS (Schierbeck et al., 2012, BMJ) showed reduced cardiovascular events.
The pharmacokinetic reference she's citing appears consistent with published data. A 2021 Scientific Reports study examining oral estradiol dosing found mean serum estradiol levels in the range she describes, though individual variability is significant. The KEEPS trial (Harman et al., 2014, Annals of Internal Medicine) used 50 mcg transdermal patches and did not show cardiovascular benefit, lending some support to the route-of-administration argument she's making.
The honest problem is that none of these trials were powered to use serum estradiol level as the primary variable for cardiovascular outcomes. Backing into a "target level" from dose-response data across separate studies is reasonable hypothesis generation, not established clinical fact.
What did they get wrong (or right)?
She got a lot right. Naming the specific trials and their designs is accurate. Flagging that serum levels were not directly reported in the RCTs and that she's cross-referencing pharmacokinetic data to estimate them, that's an honest disclosure most creators skip entirely. The caution about transdermal extrapolation is also scientifically appropriate.
Where this gets shakier is the osteoporosis claim. She states "a serum estradiol level of 60 pg/mL is needed to prevent osteoporosis." That number circulates in clinical discussions, but the bone threshold literature is messier than a single number implies. Studies like Ettinger et al. (1998) suggest benefits at lower levels, and the threshold varies by individual bone density and estrogen sensitivity.
The bigger issue is framing 65 pg/mL as a meaningful clinical target for cardiovascular protection when no RCT has actually tested serum levels as the intervention. She's connecting dots in a way that's intellectually defensible but risks sounding more definitive than the evidence allows. The leap from "this dose was cardioprotective" to "this serum level is cardioprotective" is an inference, not a finding.
What should you actually know?
If you're on oral estradiol for menopause, the evidence base for cardiovascular benefit is real but comes with conditions. It applies to younger, healthier women who start therapy within six years of menopause onset. That timing window matters. The Women's Health Initiative scared a generation off HRT partly because it enrolled older women, further from menopause, at higher baseline risk.
Serum estradiol monitoring is useful clinically, but no regulatory body or major society has endorsed a specific target level for cardiovascular protection because the RCTs didn't test levels, they tested doses in selected populations. The Menopause Society (formerly NAMS) and the British Menopause Society both acknowledge the observational and trial data supporting early initiation, but neither sets a pg/mL target.
Route of administration probably does matter for cardiovascular outcomes, though not necessarily in the way assumed. Oral estradiol raises HDL and may have hepatic first-pass effects that contribute to benefit, while transdermal bypasses that pathway. That may explain the KEEPS null result, or KEEPS may have been underpowered. Both are true at once.
Bottom line: this video is better sourced than most. But treating 65 pg/mL as a validated cardioprotective threshold overstates what the studies actually established.